The Greek philosopher Plato emphasized the importance of moderating personal desires for the functioning of society. The virtue of moderation is also critical for the live-long function of hematopoietic stem cells (HSC), the origin of all blood cells. To prevent undue activation, which can deplete HSC and increase the risk of blood cancer, HSC need to restrain signaling by phosphoinositide 3-kinases (PI3K) -a pivotal pathway whose hyperactivation contributes to many diseases [1] . Yet, the precise mechanisms limiting PI3K-signaling within HSC remain ill understood. We recently presented evidence that they include non-canonical PI3K-regulation by the little-studied enzyme inositoltrisphosphate 3-kinase B (IP 3 3-kinase B/Itpkb) in HSC [2] . Itpkb -/-mice died with HSC/hematopoietic-progenitor-cell (HPC) depletion and anemia. Thus, we speculate that defective PI3K-dampening by Itpkb or other moderators contributes to the frequent HSC-defects in bone marrow (BM) failure syndromes [3] .
an intensity-range that ensures self-renewal, but avoids activation. The underlying mechanisms are incompletely understood [1, 2] . Activated by cytokines and other signals, PI3K and its effectors Akt and mTORC1 are required for HSC self-renewal and function. But excessive PI3K/Akt activity transiently expands HSC, followed by depletion and reduced long-term engraftment associated with variable myeloproliferative disease, T-cellacute-lymphoblastic (T-ALL) or acute-myeloblasticleukemia (AML) [1, 2] . PI3K produce the membranelipid phosphatidylinositol (3, 4, 5) trisphosphate (PIP 3 ), a recruiting and activating ligand for Akt and other effectors. To prevent excessive PI3K-signaling, PIP 3 -levels in many cell types are limited through its removal by the lipidphosphatases PTEN and SHIP (references in [1, 2] 4 production by Itpkb as essential for signaling in lymphocytes, granulocyte-monocyte-progenitors (GMP) and neutrophils (references in [2, 5] ). IP 4 is identical with the protein-binding moiety of PIP 3 . In NK cells, GMP and neutrophils, IP 4 competitively limits PIP 3 -binding to and activation of Akt (references in [2] Supporting an Itpkb-role in moderating PI3K-signaling in HSC, Itpkb -/-HSC had elevated mTORC1 activity in vivo, and showed increased SCF-activation of Akt and mTORC1 in vitro. This was prevented by treatment with cell-permeable IP 4 or an Akt-inhibitor. Transcriptome-analysis suggested Akt/mTORC1-hyperactivity and increased oxidative phosphorylation and protein biosynthesis in Itpkb -/-HSC. A recent study suggests that HSC-quiescence requires restrained protein biosynthesis and implies moderation of mTOR signaling [6] . Injection of the mTOR-inhibitor Rapamycin reversed the HSC-hyperproliferation in Itpkb -/-mice [2] . Thus, we propose that Itpkb limits cytokine and PI3K/Akt/mTOR signaling in HSC to ensure quiescence and longevity ( Figure 1 . Itpkbloss might also impair PI3K-unrelated signaling events that promote neoplasia. Clarifying whether Itpkb-loss transforms hematopoietic cells will require conditional knockouts and larger aged cohorts. This will also rule out that Itpkb-loss in other cells indirectly contributes to the HSC-activation in Itpkb -/-mice [5] . Interestingly, Rapamycin reversed the HSChyperproliferation in Itpkb -/-mice but did not rescue their CFU-activity. This contrasts with PTEN -/-or myrAktexpressing HSC and may suggest that mTORC1-unrelated mechanisms contribute to HSC-control by Itpkb [2] . But Rapamycin also reduced wt HSC CFU-activity, and genetic studies suggest mTORC1-requirements for HSCregeneration and -function (references in [2] ). This might explain the difficulty of rescuing Itpkb -/-HSC-function with mTORC1-inhibitors, and raises concerns that longterm therapeutic mTORC1-inhibition to prevent aging [7] might damage HSC.
Wrapping up, Itpkb-identification as a moderator of cytokine-and PI3K-signaling in HSC advances our understanding of the HSC-intrinsic mechanisms balancing self-renewal with activation and broadens the importance of IP 4 /PIP 3 -antagonism as a non-canonical mechanism regulating PI3K-function. It will now be important to assess the human relevance of this mechanism, and to determine if human BM failure patients show diseasedriving mutations in Itpkb. Moreover, it will be interesting to explore if transient specific and selective Itpkbinhibition can mobilize or expand human HSC without impairing their function.
